A Randomized, Single-centre, Double-blind, Placebo-controlled Proof-of-concept Parallel Group Clinical Trial to Investigate the Efficacy, Safety and Tolerability of Weekly Subcutaneous Dosing of CK-0045 in Participants With Overweight/Obesity and Type 2 Diabetes

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CK 0045 (Primary)
Indications Obesity; Type 2 diabetes mellitus
Focus Proof of concept; Therapeutic Use
Sponsors Cytoki Pharma

Most Recent Events

11 Feb 2025 Planned End Date changed from 1 Sep 2025 to 1 Oct 2025.
11 Feb 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Aug 2025.
04 Nov 2024 According to Cytoki Pharma media release , Results of the study are anticipated in the first half of 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight